Abstract
The number of statistical challenges facing regulators remains high, as does the importance of statistical thinking in the regulatory decision-making process. Statisticians in the Office of Biostatistics at the US Food and Drug Administration review hundreds of new drug and therapeutic biologic applications each year and advise sponsors on protocols numbering in the thousands. In addition to remaining up to date on the newest statistical methods, statisticians are often called upon for innovative approaches to difficult regulatory problems. This article presents the author's view of the important role that statisticians play in regulatory decision making, beginning with a broad overview of current office initiatives, including the development of guidance documents and a recent push for open and transparent collaboration with industry on methods development. Several recent examples are provided to illustrate the impact that statisticians can have on regulatory decisions through the use of strategic quantitative thinking. Also discussed are areas where it is believed that innovative statistical solutions or greater clarity on existing approaches is still needed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.